Drug data · shortage, price, volume

Aprepitant capsules: listed 7 months as a shortage, and the generic benchmark price rose 3% since 2023

The FDA has listed this drug as short in the past. The pharmacy benchmark says the generic capsule now costs $78.69 each, against $130.02 in 2021. Availability and price are different measures, so this page shows both over time.

FDA shortage list, 2026-11-05NADAC, November 2026Medicaid SDUDinferred monthno data
  1. The capsule was on the FDA list from July 2015 to January 2016, 7 months, and is not listed now.
  2. 81% of shortage listings since 2014 lasted as long as this one. The median lasts 21 months.
  3. A generic 80 mg capsule costs pharmacies $78.69 on the NADAC benchmark in November 2026, 3% above its 2023 level.
  4. Medicaid paid for 3,046 capsule prescriptions in Q4 2025, 29% more than in Q4 2021.

Not medical advice. This page reports public records about supply and pharmacy cost. Ask a pharmacist or prescriber about your own medication.

Three clocks on one timeline

Each lane uses the same monthly axis, so you can read across: when the FDA listed the capsule, what pharmacies were paying, and how many Medicaid prescriptions were filled.

on the listinferred across a missing captureno capture or no price$ per capsuleprescriptionspreliminary quarter

Swipe the chart sideways to see all 10 years.

Three clocks: FDA shortage list, pharmacy acquisition cost and Medicaid prescriptionsShared monthly timeline. Top lane: months the capsule was on the FDA shortage list. Middle lane: NADAC price per capsule by strength. Bottom lane: Medicaid prescriptions per quarter. 201820192020202120222023202420252026FDA shortage listcapsule, by name2018-10 to 2018-11: no capture of the FDA list for these months2019-02 to 2019-04: no capture of the FDA list for these months2024-10 to 2025-08: no capture of the FDA list for these monthsfirst listed Jul 2015Pharmacy costNADAC, $ per capsulebold = 80 mg generic$0$75$150NADAC reported no price for this strength from 2022-07 to 2023-12$130.02 in 2021$78.69 nowMedicaid fillsprescriptions per quartercapsule2017Q1: 187 prescriptions; unsuppressed state rows only2017Q2: 345 prescriptions; unsuppressed state rows only2017Q3: 350 prescriptions; unsuppressed state rows only2017Q4: 281 prescriptions; unsuppressed state rows only2018Q1: 387 prescriptions; unsuppressed state rows only2018Q2: 397 prescriptions; unsuppressed state rows only2018Q3: 461 prescriptions; unsuppressed state rows only2018Q4: 497 prescriptions; unsuppressed state rows only2019Q1: 652 prescriptions; unsuppressed state rows only2019Q2: 783 prescriptions; unsuppressed state rows only2019Q3: 1,051 prescriptions; unsuppressed state rows only2019Q4: 1,068 prescriptions; unsuppressed state rows only2020Q1: 1,004 prescriptions; unsuppressed state rows only2020Q2: 696 prescriptions; unsuppressed state rows only2020Q3: 1,527 prescriptions; unsuppressed state rows only2020Q4: 1,689 prescriptions; unsuppressed state rows only2021Q1: 1,906 prescriptions; unsuppressed state rows only2021Q2: 2,357 prescriptions; unsuppressed state rows only2021Q3: 2,293 prescriptions; unsuppressed state rows only2021Q4: 2,361 prescriptions; unsuppressed state rows only2022Q1: 2,146 prescriptions; unsuppressed state rows only2022Q2: 2,638 prescriptions; unsuppressed state rows only2022Q3: 2,599 prescriptions; unsuppressed state rows only2022Q4: 2,428 prescriptions; unsuppressed state rows only2023Q1: 2,686 prescriptions; unsuppressed state rows only2023Q2: 2,749 prescriptions; unsuppressed state rows only2023Q3: 2,826 prescriptions; unsuppressed state rows only2023Q4: 2,750 prescriptions; unsuppressed state rows only2024Q1: 2,372 prescriptions; unsuppressed state rows only2024Q2: 2,171 prescriptions; unsuppressed state rows only2024Q3: 2,222 prescriptions; unsuppressed state rows only2024Q4: 2,626 prescriptions; unsuppressed state rows only2025Q1: 3,061 prescriptions; unsuppressed state rows only2025Q2: 3,695 prescriptions; unsuppressed state rows only2025Q3: 3,335 prescriptions; unsuppressed state rows only2025Q4: 3,046 prescriptions; unsuppressed state rows only2026Q1: 2,561 prescriptions (latest quarter, preliminary: CMS may revise); unsuppressed state rows only4k0
Top: months the capsule name was on the FDA list (Wayback captures of the FDA page). Middle: NADAC per capsule, one line per strength. Where NADAC reported no price for a strength for more than two months, the line breaks and the gap is hatched: we do not bridge missing prices. Bottom: Medicaid prescriptions per quarter. Medicaid volume: 11,818 rows pulled for this drug, 9,842 (83%) suppressed by CMS for small cells and left out, never counted as zero, so every bar is a floor; state XX national rows excluded; the hatched latest quarter is preliminary. Fills also move with Medicaid enrollment, so a change is not by itself evidence of a shortage.

How long do shortages last?

Each step is a drop in the share of FDA shortage listings still running. The dot is this drug.

Share of FDA shortage listings still running after N months, with this drug marked0%25%50%75%100%024487296120months on the FDA listmedian 21 monthsthis listing (ended): 7 mo81% lasted this long
Kaplan-Meier on 397 listings, 2014 to 2026, by ingredient. 18 months have no capture and are bridged by inference. Every listing behind this curve, with the method and a dated correction, is in the shortage length dataset.

What a pharmacy pays per unit

NADAC is the average price retail pharmacies pay, per capsule.

Pharmacy acquisition cost per unit, brand against genericCapsule 40 mg$45.11Capsule 80 mg$78.69
Thirty generic 80 mg capsules is about $2360.68 at this benchmark. It is acquisition cost, not a retail price.

Which forms are short

FDA listing by dosage form
FormListed nowMonths listedFDA records (2026-11-05)
capsuleNo (last listed January 2016)7none

Price by strength

Capsule: generic acquisition cost per capsule by strength
StrengthNow2021 medianFirst monthNow vs 2021HistoryNDCs
40 mg$45.11$64.80$75.922018-06-30%9
80 mg$78.69n/a$130.022021-07n/a16-month gap in NADAC reporting13
Read the price with care. NADAC is a national survey average of retail pharmacy invoices. It is not a quote, not what any patient paid, and it excludes discounts and rebates. A flat or falling benchmark during a shortage means pharmacies' average invoice cost did not rise, not that every patient could find the drug at that price.
FDA caution. The FDA drug shortage list is updated as manufacturers report and should not be relied on for medical care. Ask a pharmacist or prescriber about supply.

Questions

Is Aprepitant still in shortage?

The capsule is not on the FDA shortage list as of 2026-11-05. It was listed from July 2015 to January 2016. FDA says not to rely on the list for medical care; ask a pharmacist.

Did the shortage raise the pharmacy price?

In the benchmark, yes. The NADAC survey average for a generic 80 mg capsule is $78.69 in November 2026, 3% above its 2023 level. NADAC is a national average of retail pharmacy invoices, so it measures what pharmacies pay on average, not what any one patient was charged.

Did Medicaid fills fall during the shortage?

No. CMS State Drug Utilization Data shows 3,046 Medicaid-paid capsule prescriptions in Q4 2025, 29% more than in Q4 2021 (2,361). Those counts are a floor because CMS suppresses small cells, they cover Medicaid only and move with Medicaid enrollment, and they count prescriptions that were filled, not demand that went unmet. A change in fills is not by itself evidence of a shortage.

What does a pharmacy pay for 30 generic 80 mg capsules?

About $2360.68 on the NADAC benchmark ($78.69 per capsule times 30). That is acquisition cost, not a retail price: it excludes dispensing fees, discounts and rebates.

If you are trying to pay for or find this drug

Run a pharmacy, discount card, telehealth or assistance service that helps people pay for medicines? Apply to be evaluated for a page like this one, or hold a disclosed featured slot. Inclusion is earned. A slot is labelled sponsored and never implies a medical endorsement. Building a product on this data? Licence the widget or the data feed.

Cite this page

Figures are calculated from U.S. federal sources (see Data terms below) and rebuilt from dated snapshots. Cite it as:

OmniRx, "Aprepitant: FDA shortage, NADAC acquisition cost and Medicaid utilization", data as of November 2026. https://omnirx.org/drugs/aprepitant

Embed this chart

Free with attribution: paste this where you want the chart. It sizes itself to its content. A small "Powered by OmniRx" link stays in the widget; white-label licences remove it and add your own branding.

<iframe id="lx-drug-aprepitant" src="https://omnirx.org/embed/drug-aprepitant" width="100%" height="640" style="border:1px solid #e2e8f0;border-radius:10px" title="Aprepitant shortage and price timeline by omnirx.org" loading="lazy"></iframe>
<script>addEventListener('message',function(e){if(e.origin!=='https://omnirx.org')return;var d=e.data||{};if(d.type==='lx-height'&&d.slug==='drug-aprepitant'){var f=document.getElementById('lx-'+d.slug);if(f)f.height=d.height;}});</script>

Sources

Data terms. Every source above is published by a U.S. federal agency (CMS or FDA). CMS's data site labels its datasets inconsistently: of the 14 NADAC years, 5 carry the "public domain" label and 9 the "U.S. government works" label; of the 14 State Drug Utilization Data years, 6 carry the "public domain" label and 8 the "U.S. government works" label. We record each dataset's label verbatim and cite the source for every figure. Figures on this page are OmniRx calculations from those datasets, not statements by CMS or FDA, and no agency endorses this page.